CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Can Smith & Nephew’s (SN.) share price rally as NHS gets back on its feet?

By Angelique Ruzicka

13:07, 25 May 2022

Smith & Nephew website on phone screen
Smith & Nephew shares could be boosted by the NHS reducing its surgery backlog – Photo: Shutterstock

British medical technology firm Smith & Nephew (SN.), a FTSE 100 stalwart, has experienced a few volatile months as it recovers from the impact of the Covid-19 pandemic.

In July 2021, the company reported soaring sales during the second quarter and strong half-year earnings, and outlined a positive outlook as pandemic restrictions eased. However, in November the company relayed how supply chain issues were hindering sales.

Smith & Nephew is an often-overlooked stock, but as pandemic fears subside and the National Health Service (NHS) tackles its backlog of elective surgical procedures, it could well deserve more attention from traders and investors.

What is your sentiment on UK100?

Vote to see Traders sentiment!

Smith & Nephew (SN.) is a FTSE 100 stalwart

Encouraging start to the year

Smith & Nephew’s first-quarter 2022 trading update showed some promising results. Revenue was up by 3.3%, from $1,264m (£1,011m) in 2021 to $1,306m (£1,044m) for this year’s first quarter.

Established markets revenue was up 4.1%, while emerging markets increased by 14.3% from the same period last year. The company highlighted that it is seeing progress with new product development, including US regulatory clearance for its cementless knee software.

Newly appointed chief executive Deepak Nath said it was an encouraging start to the year, adding that the first-quarter performance puts the company on track to deliver on its guidance for 2022.

The market received news of the update well, and the company’s shares rose 3.4% on the back of the announcement that it had benefited from a rebound in surgical procedures.

Upside potential

Russ Mould, investment director at AJ Bell, agrees that there’s potential for the company.

“Orthopaedics to wound care to sports medicine specialist Smith & Nephew could yet be a beneficiary of anything like a return to normality in hospitals, and April’s first-quarter trading update offered hints of the upside potential.


7.48 Price
+7.700% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.07


453.45 Price
-3.090% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.49


235.29 Price
-1.640% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.33


141.73 Price
+5.400% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.63

“Sports Medicine led the way with sales growth of 6.1%, followed by Advanced Wound Management at 5.1% and then Orthopaedics at 0.3%, where hip implant revenues fell, as if to re-emphasise the upside potential if, as and when elective surgery volumes really start to recover.

“Higher volumes would again be a big help on this front. Hip and knee replacements and other surgical procedures have been crowded out by the viral outbreak at busy hospitals, and new variants have delayed the recovery in volumes. Smith & Nephew could therefore get a boost if, as and when the virus is finally beaten off,” Mould said.

Supply chain issues

Supply chain issues have been the latest thorn in the company’s side, but it’s making progress here too.

Susannah Streeter, senior investment and markets analyst at Hargreaves Lansdown, said: “While Smith & Nephew’s been struggling against supply chain headwinds, things are starting to normalise. In particular there should be significant opportunity in the group’s Sports Medicine and Orthopaedics businesses, which were both hit by delays from the pandemic.

“Demand hasn’t gone away, it’s just that operations have just been delayed, which could set the stage for a strong recovery as hospitals play catch-up. The company is now well placed to meet an expected wave of demand with a much more efficient business.”

Restructuring efforts

Profits were hampered in 2021 by higher fixed costs, but Smith & Nephew has made efforts to deal with this problem. Streeter believes the company’s strong set of financials could see it through any potential future delays.

“The group embarked on a restructuring effort designed to lower its cost base by optimising the manufacturing network and outsourcing warehousing and distribution. This project is costing around $350m but is set to save the group $200m per year by 2025.

“The group’s also got a relatively strong balance sheet, with net debt roughly two times last year’s cash profits, which also gives the group breathing room if the flood of expected surgeries takes longer to materialise and supply chain issues keep causing problems,” she said.

Related topics

Rate this article

Related reading

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading